Literature DB >> 18085737

Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial.

Dinesh Khanna1, Philip J Clements, Arnold E Postlethwaite, Daniel E Furst.   

Abstract

OBJECTIVE: The Health Assessment Questionnaire-Disability Index (HAQ-DI) is a commonly used musculoskeletal-targeted measure in systemic sclerosis (SSc). We assessed if HAQ-DI scores are different when calculated with and without aids/devices, and if apparent responsiveness changes when scored in these 2 ways.
METHODS: We used data from a placebo-controlled clinical trial in diffuse SSc. Baseline HAQ-DI total score was calculated with and without aids/devices and compared using Student's t-test. We also classified the HAQ-DI scores into no-to-mild disability (0.00-1.00), moderate disability (1.01-2.00), and severe disability (2.01-3.00). Responsiveness to change was evaluated using the effect size (ES).
RESULTS: The mean (SD) baseline HAQ-DI score was 1.33 (0.68) with aids/devices compared to HAQ-DI score 1.16 (0.70) without aids/devices (p = 0.03). When the baseline HAQ-DI score was categorized into no-to-mild, moderate, and severe disability, the proportion of patients in the no-to-mild disability (29% with aids/devices vs 44% without aids/devices) and moderate disability (59% with aids/devices vs 45% without aids/devices) groups were statistically different (p <0.001). The ES was similar between the 2 groups (ES = 0.01 and 0.02 with and without aids/devices).
CONCLUSION: This analysis suggests a shift from no-to-mild disability to moderate disability when aids/devices are incorporated in total HAQ-DI score. Future clinical trials in SSc should explicitly state whether HAQ-DI score was calculated using aids/devices.

Entities:  

Mesh:

Year:  2007        PMID: 18085737

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.

Authors:  Jing Zhou; Dong Yang; Shu-Hong Zhou; Jin-Ping Wang; Yue-Shu Liu; Shu-Lan Wang
Journal:  Chin J Integr Med       Date:  2017-02-15       Impact factor: 1.978

2.  Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study.

Authors:  Manjit K Singh; Philip J Clements; Daniel E Furst; Paul Maranian; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

3.  Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic.

Authors:  Dinesh Khanna; Paul Maranian; Nan Rothrock; David Cella; Richard Gershon; Puja P Khanna; Brennan Spiegel; Daniel E Furst; Phil J Clements; Amber Bechtel; Ron D Hays
Journal:  Value Health       Date:  2011-10-22       Impact factor: 5.725

4.  Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial.

Authors:  Puja P Khanna; Daniel E Furst; Philip J Clements; Paul Maranian; Lilavati Indulkar; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2010-02-09       Impact factor: 7.580

5.  Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.

Authors:  Tracy Frech; Ron D Hays; Paul Maranian; Philip J Clements; Daniel E Furst; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2011-02-15       Impact factor: 7.580

6.  Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.

Authors:  Sogol Amjadi; Paul Maranian; Daniel E Furst; Philip J Clements; Weng Kee Wong; Arnold E Postlethwaite; Puja P Khanna; Dinesh Khanna
Journal:  Arthritis Rheum       Date:  2009-08

7.  Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

Authors:  Dinesh Khanna; Philip J Clements; Daniel E Furst; Joseph H Korn; Michael Ellman; Naomi Rothfield; Fredrick M Wigley; Larry W Moreland; Richard Silver; Youn H Kim; Virginia D Steen; Gary S Firestein; Arthur F Kavanaugh; Michael Weisman; Maureen D Mayes; David Collier; Mary E Csuka; Robert Simms; Peter A Merkel; Thomas A Medsger; Martin E Sanders; Paul Maranian; James R Seibold
Journal:  Arthritis Rheum       Date:  2009-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.